SI1224179T1 - Sodium-hydrogen exchanger type 1 inhibitor crystals - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor crystals

Info

Publication number
SI1224179T1
SI1224179T1 SI200030449T SI200030449T SI1224179T1 SI 1224179 T1 SI1224179 T1 SI 1224179T1 SI 200030449 T SI200030449 T SI 200030449T SI 200030449 T SI200030449 T SI 200030449T SI 1224179 T1 SI1224179 T1 SI 1224179T1
Authority
SI
Slovenia
Prior art keywords
sodium
exchanger type
hydrogen exchanger
inhibitor crystals
crystals
Prior art date
Application number
SI200030449T
Other languages
English (en)
Slovenian (sl)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Pfizer Global Research and Dev. LI
Susan L. Pfizer Global Research and Dev. ORRILL
Bharat K. Pfizer Global Research and Dev. SHAH
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SI1224179T1 publication Critical patent/SI1224179T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200030449T 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals SI1224179T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
EP00962776A EP1224179B1 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (1)

Publication Number Publication Date
SI1224179T1 true SI1224179T1 (en) 2004-10-31

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030449T SI1224179T1 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Country Status (44)

Country Link
EP (1) EP1224179B1 (ko)
JP (1) JP2003512455A (ko)
KR (1) KR100464526B1 (ko)
CN (2) CN1205205C (ko)
AP (1) AP2002002493A0 (ko)
AR (1) AR029402A1 (ko)
AT (1) ATE271047T1 (ko)
AU (1) AU778573B2 (ko)
BG (1) BG106729A (ko)
BR (1) BR0015275A (ko)
CA (1) CA2389020A1 (ko)
CO (1) CO5271714A1 (ko)
CZ (1) CZ20021332A3 (ko)
DE (1) DE60012208T2 (ko)
DK (1) DK1224179T3 (ko)
DZ (1) DZ3463A1 (ko)
EA (1) EA004937B1 (ko)
EE (1) EE200200227A (ko)
ES (1) ES2222923T3 (ko)
GE (1) GEP20043222B (ko)
GT (1) GT200000180A (ko)
HK (1) HK1048472B (ko)
HR (1) HRP20020366B1 (ko)
HU (1) HUP0204009A3 (ko)
IL (1) IL148581A0 (ko)
IS (1) IS6302A (ko)
MA (1) MA26840A1 (ko)
MX (1) MXPA02004358A (ko)
NO (1) NO20021821L (ko)
NZ (1) NZ517738A (ko)
OA (1) OA12080A (ko)
PA (1) PA8505501A1 (ko)
PE (1) PE20010764A1 (ko)
PL (1) PL354869A1 (ko)
PT (1) PT1224179E (ko)
SI (1) SI1224179T1 (ko)
SK (1) SK5312002A3 (ko)
SV (1) SV2002000209A (ko)
TN (1) TNSN00210A1 (ko)
TR (1) TR200201167T2 (ko)
UA (1) UA72002C2 (ko)
WO (1) WO2001030759A2 (ko)
YU (1) YU31502A (ko)
ZA (1) ZA200203295B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
MXPA03006872A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Etanolatos del inhibidor del intercambiador de sodio-hidrogeno de tipo 1.
BR0307195A (pt) * 2002-01-30 2004-11-03 Pfizer Prod Inc Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056729B1 (en) * 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
NZ517738A (en) 2005-06-24
PA8505501A1 (es) 2003-09-05
GT200000180A (es) 2002-04-11
TR200201167T2 (tr) 2002-08-21
KR100464526B1 (ko) 2005-01-03
ATE271047T1 (de) 2004-07-15
OA12080A (en) 2003-08-25
EE200200227A (et) 2003-06-16
CN1636991A (zh) 2005-07-13
PL354869A1 (en) 2004-03-08
BR0015275A (pt) 2002-07-16
AP2002002493A0 (en) 2002-06-30
CZ20021332A3 (cs) 2002-10-16
WO2001030759A2 (en) 2001-05-03
HUP0204009A3 (en) 2004-07-28
HK1048472A1 (en) 2003-04-04
IS6302A (is) 2002-03-15
IL148581A0 (en) 2002-09-12
GEP20043222B (en) 2004-04-26
ES2222923T3 (es) 2005-02-16
CN1384829A (zh) 2002-12-11
EA200200416A1 (ru) 2002-10-31
CA2389020A1 (en) 2001-05-03
NO20021821D0 (no) 2002-04-18
MXPA02004358A (es) 2002-11-07
SK5312002A3 (en) 2003-01-09
DZ3463A1 (fr) 2001-05-03
AU7441500A (en) 2001-05-08
ZA200203295B (en) 2003-06-25
HRP20020366B1 (en) 2005-04-30
AU778573B2 (en) 2004-12-09
HRP20020366A2 (en) 2004-02-29
CO5271714A1 (es) 2003-04-30
CN1205205C (zh) 2005-06-08
YU31502A (sh) 2004-12-31
WO2001030759A3 (en) 2001-09-13
SV2002000209A (es) 2002-07-16
PT1224179E (pt) 2004-10-29
HUP0204009A2 (hu) 2003-03-28
UA72002C2 (en) 2005-01-17
JP2003512455A (ja) 2003-04-02
KR20020040918A (ko) 2002-05-30
MA26840A1 (fr) 2004-12-20
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
DE60012208D1 (de) 2004-08-19
EP1224179B1 (en) 2004-07-14
DE60012208T2 (de) 2005-07-21
EP1224179A2 (en) 2002-07-24
EA004937B1 (ru) 2004-10-28
HK1048472B (zh) 2005-09-16
TNSN00210A1 (fr) 2005-11-10
BG106729A (bg) 2002-12-29
NO20021821L (no) 2002-04-18
DK1224179T3 (da) 2004-10-25

Similar Documents

Publication Publication Date Title
TW535893U (en) Heat exchanger
EP1164345A4 (en) Heat Exchanger
IL130438A (en) Heat exchanger
GB9919634D0 (en) Heat exchanger
SG78411A1 (en) Filter-heat exchanger
PL342763A1 (en) Matrix metaloprotease inhibitor
EP1136783A4 (en) HEAT EXCHANGER
GB2343643B (en) Heat exchanger
IL148581A0 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals
DZ3310A1 (fr) Inhibiteurs de l'echangeur sodium-hydrogene de type 1
GB9928207D0 (en) Heat exchanger
IL139198A0 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
GB9824648D0 (en) Heat exchanger
EP1256771A4 (en) HEAT EXCHANGER
GB9926629D0 (en) Heat exchangers
GB2338293B (en) Heat exchanger
GB9901538D0 (en) Heat exchanger
GB9803871D0 (en) Heat exchanger
EP1111322A4 (en) HEAT EXCHANGER
GB9827817D0 (en) Type 11 Dehydroquinase inhibitors
GB9811892D0 (en) Heat exchanger
GB9824493D0 (en) Heat exchanger
IL148749A0 (en) Heat exchanger
GB9826956D0 (en) Heat exchanger
GB9818707D0 (en) Heat exchanger